Illumina, Inc. (NASDAQ:ILMN) SVP Charles Dadswell sold 145 shares of the stock in a transaction that occurred on Wednesday, January 3rd. The stock was sold at an average price of $224.50, for a total value of $32,552.50. Following the sale, the senior vice president now directly owns 7,411 shares in the company, valued at approximately $1,663,769.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Charles Dadswell also recently made the following trade(s):
- On Monday, December 4th, Charles Dadswell sold 145 shares of Illumina stock. The stock was sold at an average price of $225.33, for a total value of $32,672.85.
- On Friday, November 3rd, Charles Dadswell sold 1,609 shares of Illumina stock. The stock was sold at an average price of $207.88, for a total value of $334,478.92.
Shares of Illumina, Inc. (NASDAQ:ILMN) traded up $2.67 on Friday, hitting $232.99. The stock had a trading volume of 862,400 shares, compared to its average volume of 858,067. Illumina, Inc. has a one year low of $132.02 and a one year high of $233.54. The company has a market cap of $33,060.00, a PE ratio of 43.96, a price-to-earnings-growth ratio of 3.15 and a beta of 0.79. The company has a quick ratio of 3.73, a current ratio of 4.22 and a debt-to-equity ratio of 0.41.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Tuesday, October 24th. The life sciences company reported $1.11 EPS for the quarter, beating the Zacks’ consensus estimate of $0.99 by $0.12. Illumina had a return on equity of 19.42% and a net margin of 30.34%. The company had revenue of $714.00 million during the quarter, compared to analysts’ expectations of $692.77 million. During the same period in the prior year, the company earned $0.97 EPS. Illumina’s revenue was up 17.6% compared to the same quarter last year. research analysts anticipate that Illumina, Inc. will post 3.75 earnings per share for the current fiscal year.
A number of equities research analysts recently issued reports on ILMN shares. Barclays increased their price target on Illumina from $150.00 to $185.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 25th. Zacks Investment Research upgraded Illumina from a “hold” rating to a “buy” rating and set a $229.00 target price for the company in a research note on Friday, October 27th. Canaccord Genuity restated a “buy” rating and set a $230.00 target price (up from $215.00) on shares of Illumina in a research note on Thursday, October 12th. Piper Jaffray Companies restated an “overweight” rating and set a $226.00 target price (up from $202.00) on shares of Illumina in a research note on Monday, October 9th. Finally, Janney Montgomery Scott upgraded Illumina from a “sell” rating to a “neutral” rating in a research note on Monday, October 23rd. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and fifteen have given a buy rating to the company. Illumina currently has a consensus rating of “Buy” and an average target price of $207.74.
A number of large investors have recently made changes to their positions in ILMN. Advisory Services Network LLC raised its position in Illumina by 13.0% during the 2nd quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock worth $134,000 after purchasing an additional 89 shares during the last quarter. Dupont Capital Management Corp acquired a new stake in shares of Illumina in the 3rd quarter valued at about $153,000. Patten Group Inc. grew its stake in shares of Illumina by 71.1% in the 3rd quarter. Patten Group Inc. now owns 1,480 shares of the life sciences company’s stock valued at $172,000 after buying an additional 615 shares during the period. West Coast Financial LLC acquired a new stake in shares of Illumina in the 3rd quarter valued at about $216,000. Finally, Los Angeles Capital Management & Equity Research Inc. acquired a new stake in shares of Illumina in the 2nd quarter valued at about $226,000. 91.60% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “Illumina, Inc. (ILMN) SVP Charles Dadswell Sells 145 Shares” was originally posted by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://transcriptdaily.com/2018/01/05/illumina-inc-ilmn-svp-charles-dadswell-sells-145-shares.html.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.